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ABSTRACT 
Lysosomal storage disorders are currently treated by enzyme replacement therapy (ERT)
through the direct administration of the unprotected recombinant protein to the patients.
Herein we present an ionically crosslinked polyelectrolyte complex (PEC) composed of
trimethyl chitosan (TMC) and -galactosidase A (GLA), the defective enzyme in Fabry
disease,  with  the  capability  of  directly  targeting  endothelial  cells  by  incorporating
peptide  ligands  containing  the  RGD  sequence.  We  assessed  the  physicochemical
properties, cytotoxicity and hemocompatibility of RGD-targeted and un-targeted PECs,
the uptake by endothelial  cells  and the intracellular  activity  of  PECs in cell  culture
models  of  Fabry  disease.  Moreover,  we also  explored  the  effect  of  different  freeze-
drying procedures in the overall activity of the PECs. Our results indicate that the use of
integrin-binding RGD moiety within the PEC increases their uptake and the efficacy of
the  GLA enzyme,  while  the  freeze-drying  allows  keeping  intact  the  activity  of  the
therapeutic protein. Overall, these results highlight the potential of TMC-based PECs as
a highly versatile and feasible drug delivery system for improving the ERT of lysosomal
storage disorders. 
KEYWORDS: Fabry  disease,  Enzyme  Replacement  Therapy,  Polyelectrolyte
Complexes, Lysosomal Delivery, α-galactosidase A, Nanomedicine, Trimethyl chitosan
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1. INTRODUCTION
Lysosomal  storage  disorders  (LSDs)  comprise  a  group  of  rare  inherited  chronic
diseases  characterized  by  the  deficiency  of  specific  enzymes  at  the  lysosomal
compartment,  and  the  accumulation  within  these  organelles  of  the  macromolecular
compounds catabolized by those enzymes.1 Although individual LSDs have incidences
of  less  than  1:100,000,  as  a  group  the  incidence  is  calculated  to  be  1  in  7,700.2
Nowadays, pharmacological treatment is only available for few of the about 50 known
LSDs.  In most cases such treatment is based on enzyme replacement therapy (ERT), in
which purified recombinant enzyme is infused into the patient. Generally, the efficacy of
many ERTs is limited due to the fact that exogenously provided enzymes do not have
effect on all clinical aspects of the disease, partly due to the irreversibility of some of
them, but also due to enzyme formulations failure to reach all major target organs in
therapeutically efficacious doses.3 Thus, delivery of therapeutic biomacromolecules to
specific cellular types and subcellular compartments is a key objective in drug delivery.
In particular, lysosomal targeting and delivery in various specific tissues has become of
great interest due to the clinical relevance of enzymes and proteins acting within the
lysosome. 
Nanoparticle-based drug delivery has been used to improve the activity and delivery
of  therapeutic  macromolecules,  like  proteins  and  DNA,  providing  longer  blood
circulation times and protecting sensitive biomacromolecules from protease degradation
and immune system reactions.4 Within the context of protein delivery systems, stimuli-
triggered release is an appealing and promising approach, especially with the use of
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physiological  stimuli  like  the  pH  drop  within  endo-lysosomal  compartments.5,  6 In
addition, addressing clinically relevant end points by targeted delivery has emerged as
an  approach  to  maximize  the  efficiency  of  a  therapeutic  macromolecule  by  strictly
localizing  its  pharmacological  activity  through  controlled  biodistribution.7,  8 Drug
delivery to the nucleus or cytoplasm has been extensively explored,9 however, lysosomal
delivery has only lately turned into the focus of attention.5, 10-17 
The current ERT therapy relies in the natural cellular transit of lysosomal enzymes.
As a rule, lysosomal enzymes are produced in the endoplasmic reticulum, glycosylated
at  the  Golgi  apparatus,  where  the  mannose-6-phosphate  (M6P)  is  added,  and  then
secreted to the extracellular space. Thereafter, the enzyme is available for the cells to be
internalized  through  M6P  receptors  and  localized  in  the  lysosomes.  This  is  the
mechanism that allows the ERT18 and the reason why enzymes administered by ERT
have been genetically modified to exhibit  an increased glycosylation,  allowing better
interactions  through  cell-surface  receptors  that  recognize  the  carbohydrate  moieties.
However, alternative enzyme targeting approaches might be necessary to enhance not
only the lysosomal destiny of the enzyme but also enzyme accumulation in specific cell
types. 
α-galactosidase A (GLA) is the lysosomal enzyme responsible for the degradation of
globotriaosylceramide (Gb3) and other neutral glycosphyngolipids. Its deficiency causes
the Fabry disease, resulting in the accumulation of Gb3 in the lysosomes of various cells
and tissues, mainly at the vascular endothelium.19-21 Therefore, endothelial cells (EC)
represent  a  main  target  for  therapeutical  intervention  in  Fabry  disease.  Target
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determinants like E-selectin, VCAM-1, ICAM-1 and integrins like αvβ3 and αvβ5 with
expression restricted to EC and upregulated during inflammation or angiogenesis, may
help to achieve specific and safe delivery of drugs into EC subsets involved in diseases,
thereby improving pharmacological efficacy.22, 23 Peptide ligands containing the arginine-
glycine-aspartic acid (RGD) sequence display a strong binding affinity and selectivity to
integrins, particularly to integrin αvβ3, and have been conjugated to several conventional
therapeutic agents for EC targeting and endosomal delivery.24-27
Previously, we have described for the first time the development of a pH-responsive
nanocarrier  for  lysosomal  delivery  of  proteins,  based  on  the  ionotropic  gelation  of
complexes between trimethyl chitosan (TMC) and the lysosomal enzyme GLA, with
triphosphate  ions.5 With  a  good  protein  loading  efficiency  (around  65%),  these
polyelectrolyte  complexes  (PECs)  have  appropriate  physicochemical  properties  to
remain  stable  at  physiological  temperature  and pH (around 7.5),  and dissociate  and
release the protein content at endosomal/lysosomal values (pH 4.5 to 5.5). We proved
that these PECs were efficiently internalized by human cells and mostly accumulated in
lysosomal compartments, demonstrating their enormous potential as advanced protein
delivery systems for treatment of lysosomal storage diseases.5
Following these results,  in  this  work we evaluated the intracellular  activity  of the
PECs, and the possibility to enhance the efficacy of the TMC-based PECs to deliver
GLA into the lysosomes of EC by introducing RGD motifs (PEC-RGD). We therefore
prepared  PEC  and  PEC-RGD  and  assessed  their  physicochemical  properties,
cytotoxicity  and  hemocompatibility,  as  well  as  cellular  uptake  by  ECs.  We  further
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investigated the intracellular activity in primary cultures of mouse aortic endothelial
cells of GLA deficient mice (MAEC KO cells). In view of optimizing the PEC storage
conditions,  we  also  explored  the  freeze-drying  process  and  the  effect  on  the  GLA
activity.
2. EXPERIMENTAL SECTION
2.1 Synthesis of N-trimethyl chitosan 
Trimethyl chitosan (TMC) was prepared from chitosan middle-viscous (CS, Fluka)
via a two-step procedure,28 as reported previously.5 Briefly, a mixture of 2 g of sieved
chitosan, 4.8 g of sodium iodide (NaI), 11 mL of a 15% aqueous sodium hydroxide
(NaOH)  solution  and  11.5  mL  of  methyl  iodide  (CH3I)  in  80  mL  of  1-methyl-2-
pyrrolidinone was stirred at 60 °C for 1 h. Special care was taken to keep the methyl
iodide in the reaction mixture by using a Liebig condenser. The product was precipitated
using ethanol and thereafter isolated by centrifugation. The N-trimethyl chitosan iodide
obtained after this first step was washed twice with ether on a glass filter to remove the
ethanol. It was then dissolved in 80 mL of 1-methyl-2-pyrrolidinone and heated to 60ºC,
thus removing most of the absorbed ether. Subsequently, 4.8 g of NaI, 11 mL of 15%
NaOH solution and 7 mL of CH3I were added with rapid stirring and the mixture was
kept at 60 °C for 30 min. Additional 2 mL of CH3I and 0.6 g of NaOH pellets were
added and the stirring was continued for 1 h. The product, precipitated with ethanol as
described above, was dissolved in 40 mL of a 10% sodium chloride (NaCl) aqueous
solution to exchange the iodide. The polymer was precipitated with ethanol, isolated by
centrifugation and thoroughly washed with ethanol and ether. In vacuum drying yielded
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a white, water-soluble product. Finally, it was dissolved in water and freeze-dried (freeze
dryer ALPHA 1-4 LD, Christ). The product was partially quaternized chitosan with ca.
50% of quaternary amines and around 28% degree of primary amines (free amines), as
determined by 1H NMR. We also observed 22 and 31% of O-methylation for C-3 and
C-6, respectively.29 The molecular weight of the TMC was estimated to be 202000 g
mol-1 with a polydispersity of 2.6,  via gel permeation chromatography (GPC), using
Ultrahydrogel 250 and 500 columns and a Waters 24/4 IR detector, in acetate buffer 0.5
M, pH 3. Dextran standards were employed for calibration. The product had a pKa value
of 6.1 and was fully soluble in both water and HEPES buffer at pH 7.4 to 7.5.
2.2 Fluorescently labeled TMC (TMC-Atto) 
TMC was conjugated to the fluorescent dye Atto 647N NHS ester (Fluka). Atto 647N
NHS was first dissolved in dimethyl sulfoxide (DMSO) and then diluted with buffer
HEPES 10 mM pH 7.4. This solution was added to a TMC solution (in HEPES 10 mM
pH  7.4)  in  an  approximate  molar  ratio  of  3:1,  and  left  to  react  for  1  h  at  room
temperature under magnetic stirring. Atto 647N-conjugated TMC was separated from
the free dye using Zeba desalt spin columns (Thermo Scientific). In order to increase the
amount of conjugated Atto 647N, a second step was performed and the product was
reacted with freshly prepared Atto 647N NHS solution for another hour and, afterwards,
separated with Zeba desalt spin columns. The dye-modified TMC (TMC-Atto) solution
was  freeze-dried  (freeze  dryer  VirTis  Freezemobile  25L,  SP  Scientific,  UK).  The
amount  of  dye  was  estimated  to  be  0.32  moles  dye  per mol  TMC,  via  UV-visible
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spectrometry (NanoDrop Spectrophotometer ND-1000, Thermo Scientific). TMC-Atto
was stored at -20 ºC.
2.3 RGD-peptide conjugation to TMC (TMC-RGD) 
A RGD cyclic peptide c(RGDfK) derivatized with N-succinimidyl S-acetylthioacetate
(SATA) through the -amine of the lysine was obtained following procedures previously
described.11, 30, 31 Briefly, the linear peptide was synthesized using standard SPPS on a 2-
chlorotrityl chloride resin. After cleavage with Acetic Acid/TFE/DCM (1:1:3), peptide
was cyclized by treatment of T3P in EtOAc in presence of TEA and DMAP. The final
cyclic peptide was deprotected with a mixture of water and TFA (1:19) and purified by
semiprep RP-HPLC obtaining peptide c(RGDfK) (180.9 mg, 15%) as a white solid. To a
solution of peptide c(RGDfK) (75.9 mg) dissolved in 15 mL of borate buffer 0.02 M at
pH 8.2 was added 10 equivalents of SATA (290 mg), the reaction mixture was stirring
during  16  h.32 After  the  completion  of  the  reaction,  the  crude  was  evaporated  and
purified by semiprep RP-HLPC, obtaining the final peptide c(RGDfK)-SATA as a solid
(13 mg, 14%). 
The  obtained  peptide  was  then  conjugated  to  TMC  via  a  N-[γ-
maleimidobutyryloxy]sulfosuccinimide  ester  crosslinker  (sulfo-GMBS,  Pierce).  First,
c(RGDfk)-SATA was left overnight at room temperature and under stirring in a solution
of EDTA 30 mM and NH2OH.HCl 50 mM to eliminate the acetyl  protecting group
yielding c(RGDfk)-sulfhydrylacetamide. In a second step, sulfo-GMBS was added to a
TMC solution (10 mg mL-1 in buffer HEPES 10 mM pH 7.5) in a concentration of 1
mM and left to react for 60 min under stirring at room temperature. Next, the product
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was separated from the non-reacted crosslinker using Zeba desalt spin columns (Thermo
Scientific) previously washed 3 times with HEPES buffer solution. This product (TMC-
crosslinker) was then incubated with the c(RDGfk)-sulfhydrylacetamide for 1 h at room
temperature and under constant stirring. Finally, the TMC-RGD product was separated
from the non-reacted c(RGDfk)-sulfhydrylacetamide using Zeba desalt spin columns,
freeze-dried  (freeze  dryer  ALPHA 1-4  LD,  Martin  Christ  Gefriertrocknungsanlagen
GmbH) and stored at -20 ºC. 
The  bicinchoninic  acid  (BCA)  assay  (Micro  BCA  Protein  Assay  Kit,  Thermo
Scientific) was used to verify the presence of the RGD peptide in the TMC (TMC-
RGD), and contrasted with the TMC. Solutions  of both polymers  (TMC and TMC-
RGD, as well as a blank of buffer) were incubated at 37 ºC for 2 h with the BCA assay
reagents and, afterwards, the absorbance at 562 nm was measured.
The  BCA  assay  is  regularly  used  to  determine  protein  concentration  in  several
samples, as the absorbance at 562 nm of the sample after incubation with the BCA assay
reagents  (a  BCA/copper  complex  is  formed),  is  linear  with  increasing  protein
concentration  due  to  the  complex  formed  (peptide-copper  chelates).  In  the  case  of
peptides smaller than 2000 Da, the BCA assay is not suggested for quantization because
the absorbance (complex formation) is dependent on the macromolecular structure of
the protein, the number of peptide bonds, as well as the presence of cysteine, tryptophan
and tyrosine.33 Nevertheless, a significant difference in absorbance at 562 nm for TMC
and TMC-RGD treated  solutions  (light  blue  and  purple,  respectively)  was  detected,
corroborating  the  presence  of  the  RGD  peptide  in  the  TMC-RGD  samples.  In
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consequence,  a  calibration  curve  was  made  by  performing  the  microBCA  test  on
solutions of the free c(RGDfk) at concentration from 0 to 6 μg mL-1, in parallel to the
samples  of  TMC  and  TMC-RGD.  A  number  of  7  RGD  moieties  per  TMC-RGD
molecule was estimated.
2.4 Polyelectrolyte complexes formation 
Recombinant GLA was produced in the HEK 293F cell line and purified by affinity
chromatography. Briefly, the suspension-adapted human embryonic kidney (HEK) cell
line  FreeStyle™ 293-F (Invitrogen™, Life  Technologies,  ref.  R790-07)  was used  to
produce GLA by polyethylenimine (PEI)-mediated transient gene expression. Details of
GLA production and purification have been previously described.34
Polyelectrolyte  complexes  (PECs)  between  GLA  and  TMC  were  prepared  by
ionotropic  gelation  with  penta-sodium  triphosphate  (TPP,  Fluka).5 The  PECs  were
obtained by adding TMC solution (solution A) to GLA (+ TPP) solution (solution B) in
a volume ratio 70:30, followed by vortex mixing for 5 s and 30 min incubation at room
temperature. For neat PECs, solution A: 35  g mL-1 of TMC, while for fluorescently
labeled  PECs (PEC-Atto),  solution  A:  35  g mL-1 of  TMC:TMC-Atto  (70:30 mass
ratio). Solution B was always 70 g mL-1 GLA and 23 g mL-1 TPP. All solutions were
in buffer HEPES 10 mM, pH 7.4-7.5. The final GLA concentration of the suspension
was 21 g mL-1.
For RGD decorated PECs (PEC-RGD), first, TMC solution (35 g mL-1) was added to
solution B, and mixed for 5 s. Then, TMC-RGD solution (35 g mL-1) was added to the
mixture, vortex mixed for 5 s and 30 min incubation at room temperature. The mass
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ratio TMC:TMC-RGD was varied between 100:0 and 50:50, and the final volume ratio
between TMC solution (TMC+TMC-RGD) and solution B was always 70:30.
Fluorescently labeled PEC-RGD (PEC-Atto-RGD) were obtained as PEC-RGD but
replacing TMC solution for (TMC:TMC-Atto solution 70:30 mass ratio). The mass ratio
between  TMC:TMC-Atto:TMC-RGD was  20:30:50.  The  final  volume ratio  between
TMC solution (TMC+TMC-Atto+TMC-RGD) and solution B was 70:30.
All PECs were characterized and used as obtained,  without further  purification or
separation steps. When necessary, they were stored at 4 ºC.
2.5 Freeze-drying of PECs
Prior to freeze drying (FD), the eutectic point of PEC suspensions was determined by
means  of  resistivity  measurements,  using  an  Autolab  PGSTAT  12  potentiostat
(EcoChemie, NL). In all samples tested, the eutectic point was within the temperature
range from  -23.3 ºC to -24.5 ºC. Therefore, freezing at -40 ºC (the standard freezing
temperature of the employed freeze-dryer) seemed a reasonable safety limit (without
relevant  loss  of  sublimation  motive  strength),  even  if  lower  temperatures  were  also
tested when freezing in liquid nitrogen.
FD vials (4 mL) were filled with 1 mL PECs suspension. A LyoMega-30 freeze-dryer
(Telstar,  Terrassa,  Spain)  equipped  with  product  temperature  probes  was  used.
Moreover, 40 μL of a 5% mannitol solution in HEPES 10 mM, pH 7.4 were added in
half of the samples in order to get isoosmotic solutions. The conditions for the different
freeze-drying cycles tested are detailed in Table 1. All freeze-dried PECs were stored at
4 ºC, and before characterization 1 mL of ultrapure water was injected inside the vials
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for  resuspension.  Samples  were  thereafter  identified  with  the  freeze-drying  cycle
employed (FD1, FD2 or FD3), and an M in case mannitol was introduced.
Table 1. Freeze-drying protocols used with PECs
FD1 FD2 FD3
Chamber T at product entrance (ºC) 25 -40 -40
Product T at entrance (ºC) 25 4 -120
Freezing T (ºC) -40 -40 -40
Sublimation T (ºC) +20 +20 +20
Final T (ºC) +30 +30 +30
Condenser T (ºC) -50 -50 -50
Vacuum limit (µmHg) 300 300 300
Total duration (h) 30 24 18
2.6 Dynamic light scattering characterization
Size  and size  distribution  of  PECs was  characterized  by  dynamic  light  scattering
(DLS) based on intensity.  The instrument (Zetasizer Nano ZS, Malvern Instruments)
was equipped with a He-Ne laser (λ=633 nm) as the incident beam, and folded capillary
cells were used. The average size (D), polydispersity index (PDI) and Zeta potential (ξ-
potential) values were determined at 25 ºC. The PDI describes the width of the particle
size  distribution,  and  scale  ranges  from  0  (monodisperse)  to  1.  For  a  single  size
population following a Gaussian distribution,  then the  PDI is related to the standard
deviation (σ) of the distribution in the fashion: PDI=(σ/D)2.
2.7 Cell line cultures
13
Human microvascular endothelial cell line CDC/EU.HMEC-1 (HMEC-1) cells were
provided by Centers for Disease Control and Prevention (CDC-NIDR)  and maintained
in MCDB 131 supplemented with 50 units mL-1 penicillin, 50 μg mL-1 streptomycin, 10
mM  L-glutamine and 10% fetal bovine serum (FBS). HeLa cells, from human cervix
carcinoma were obtained from ATTC and maintained in RPMI media supplemented
with FBS, antibiotics and L-glutamine. Both cell lines were kept in a 37 ºC humidified
atmosphere with 5% CO2. Media, sera and antibiotics were purchased from Invitrogen.
2.8 Cytotoxicity and hemocompatibility of PECs
Biocompatibility  of  PECs was  evaluated  as  previously  described.35,  36 Briefly,  cell
cytotoxicity  was  tested  using  3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium
bromide (MTT) on HeLa and HMEC-1 cells. Cells were exposed to different doses of
PECs (PEC or PEC-RGD) during 72 h, and at the end of the incubation period, 5 mg
mL-1 of MTT solution was added to the wells. Formazan crystals were dissolved with
DMSO and spectrophotometrically measured at 590 nm (Biotek ELx800 Absorbance
Microplate Reader, Izasa Scientific). The data are expressed as the percentages of viable
cells compared to the cell survival of a control non-treated group. 
For hemocompatibility tests, mouse red blood cells (RBC) were isolated from three
wild type C57BL6 mice,  resuspended in 2% (v/v)  in  PBS and exposed to  different
concentrations of PECs during 1 h at 37 ºC.  The amount of hemoglobin released was
measured in a spectrophotometer at 405 nm (Biotek ELx800) and referred to a positive
control of 100% hemolysis obtained after incubating RBC with 1% of Triton-X.
2.9 Cell internalization
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To study the integrin mediated internalization of PECs, HMEC-1 cells were incubated
with Atto 647-labeled PECs (12.5 g mL-1) resuspended into MCDB 131 without FBS
for  10 or  20 min  at  37  ºC.  Cells  were  subsequently  washed twice  with  Dulbecco’s
phosphate buffered saline (DPBS) solution and subjected to fluorescence-activated cell
sorting (FACS) analysis. Data acquisition and analysis was performed using FACScan
(Beckton-Dickinson) and BD FACSDiva software. A minimum amount of 104  viable
cells were evaluated in each experiment and the percentage of positive cells as well as
mean fluorescence intensity (MFI) were recorded. 
2.10 Specific enzymatic activity 
GLA enzymatic activity was assayed fluorometrically as described by Desnick et al.37
with  the  modifications  of  Mayes  et  al.38 Basically,  it  was  assayed  by  using  4-
Methylumbelliferyl α-D-galactopyranoside (4-MUG, Sigma Chemical) as substrate, at a
concentration of 2.46 mM in assay buffer (0.01 M acetic acid, pH 4.5). A typical assay
reaction mixture contains  100 µL of  substrate  and 25 µL of the sample.  Enzymatic
reactions took place in agitation (tubes placed in a rotator, set at a rotation speed of 25
rpm), at 37 ºC for 1 h, and were stopped with 1.25 mL of 0.2 M glycine buffer (pH
10.4).  The  released  product,  4-methylumbelliferone  (4-MU),  was  determined  by
fluorescence measurement at 365 and 450 nm as excitation and emission wavelengths,
respectively. Samples of commercial 4-MU (Sigma Chemical) ranging from 5 to 500 ng
mL-1 in 0.2 M glycine buffer pH 10.4, were used to obtain a calibration curve in order to
transform fluorescence readings into 4-MU concentration. Specific enzymatic activities
are expressed as “µmol4-MU mgGLA-1 h-1”, or as activity concentrations (U/mL). 
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2.11 NBD-Gb3 assays in endothelial primary cultures of Fabry mice
Primary cultures of mouse aortic endothelial cells (MAEC) of GLA deficient mice
(GlatmKul1) were isolated at the ICTS ‘NANBIOSIS’, more specifically the CIBER-
BBN’s  In  Vivo Experimental  Platform  at  the  Functional  Validation  &  Preclinical
Research  (FVPR)  area  (www.nanbiosis.es/unit/u20-in-vivo-experimental-platform),
following procedures previously described.11, 39 Endothelial origin of isolated cells was
confirmed by CD105 staining. For activity assays, cells in passages 2 to 5 were seeded
in 24 well plates and maintained at 37 ºC and 5% of CO2. 24 h after seeding 8 µM of
fluorescent  N-Dodecanoyl-NBD-ceramide trihexoside (NBD-Gb3, Matreya LCC) was
added to the cultures along with the specified concentrations of tested compounds (free
GLA  enzyme,  freshly  prepared  PEC,  PEC-RGD,  freeze-dried  PEC).  After  48  h
incubation,  cells  were trypsinized and NBD-Gb3 fluorescent  signal was analyzed by
flow cytometry (FacsCalibur,  Beckton Dickinson) and FCS Express v4 software.  To
calculate the percentage of NBD-Gb3 signal, fluorescent signal in control cells (without
treatment) was established as 100% and the values were normalized accordingly. Since
GLA activity reduces those Gb3 deposits, the percentage of Gb3 loss (% Gb3 loss = 100
-% Gb3-NBD signal)  was used to  plot  the results.  When needed,  IC50 values were
calculated using GraphPad Prism 5 software. 
2.12 Animal experimentation
C57Bl6 wild type animals and Glatm1Kul GLA deficient mice40 were used as source of
red blood cells and MAEC, respectively. Animal care was handled in accordance with
the Guide for the Care and Use of Laboratory Animals of the Vall d’Hebron University
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Hospital Animal Facility, and following experimental procedures previously approved
by the Animal Experimentation Ethical Committee at the institution.
3. RESULTS 
3.1 Preparation and characterization of RGD-conjugated and fluorescently labeled
PECs
The polyelectrolyte  complexes  (PECs)  between  GLA and  TMC were  prepared  by
ionotropic  gelation  with  penta-sodium  triphosphate,  as  previously  reported,5 and
characterized by DLS. We obtained particles with diameters in the range of 170 to 215
nm at room temperature, and ξ-potential values around 19 mV (Table 2).
To obtain RGD-conjugated-PECs (PEC-RGD), the mass ratio TMC:TMC-RGD was
varied between 100:0 and 50:50, and the PECs were prepared and characterized by
DLS. We found that the incorporation of TMC-RGD lead to a slight decrease of PECs
zeta potential value (19 mV for PEC and 17 mV for PEC-RGD) with no significant
variation of the average diameter when up to 50% TMC was replaced by TMC-RGD
(Table 2). In view of the small change observed for the system, we performed additional
studies with the PEC-RGD obtained using a TMC:TMC-RGD mass ratio of 50:50.
In a similar manner, TMC was replaced in part by TMC-Atto to obtain fluorescently
labeled  PECs  (PEC-Atto),  or  by  TMC-RGD and  TMC-Atto,  to  obtain  fluorescently
labeled RGD-conjugated PECs (PEC-Atto-RGD) (see Experimental section). As shown
in Table 2, the introduction of the fluorochrome did not significantly alter the PECs size.
The ξ-potential of both PEC-Atto and PEC-Atto-RGD was around 16 mV, slightly lower
than that for PEC. PEC labeled Atto 647N have been characterized by single-molecule
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fluorescence in a previous report,5 revealing that they were homogeneous in size and
possessed good colloidal stability in water/HEPES and serum free cell culture medium. 
 Table 2. DLS average diameter D, PDI and ξ-potential of PEC, PEC-RGD, PEC-Atto
and PEC-Atto-RGD, in 10 mM HEPES buffer pH 7.5, at 25 ºC. Depicted results are the
average from 3 independent samples. 
Average size 
D 
(Mean ± SD) (nm)
PDI 
(Mean ± SD) 
ξ-potential
(Mean ± SD) 
(mV)
PEC 177 ± 30 0.19 ± 0.08 18.7 ± 3.9
PEC-RGD 186 ± 11 0.21 ± 0.04 17.0 ± 2.5
PEC-Atto 241 ± 19 0.12 ± 0.03 16.4 ± 3.4
PEC-Atto-RGD 212 ± 30 0.13 ± 0.03 16.7 ± 2.9
3.2 Physico-chemical characterization of freeze-dried PEC
PEC  suspensions  were  freeze-dried  following  3  different  freezing  protocols  (see
Experimental section). PECs were characterized within 24 h after preparation, whereas
freeze-dried PECs were characterized immediately after resuspension.
Remarkable  differences  were  observed between different  FD cycles  (see  Table  3).
Regarding particle size, a notable reduction in the average diameter was observed when
using FD2 cycle, resulting in a compaction of the particles, and the addition of mannitol
did not cause any particle size increase. Instead, when freeze-drying following FD1 and
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FD3  cycles,  a  slight  diameter  increase  was  observed,  being  almost  twofold  when
mannitol  was  added.  On  the  other  hand,  higher  PDI  values  were  obtained  for  all
particles after freeze-drying, even if these were lower than 0.3 for PEC-FD1, PEC-FD2
and  PEC-FD2-M,  which  are  still  acceptable  PDI  values.  Besides,  minor  ξ-potential
decrease  was  observed  after  freeze-drying  by  cycles  FD1  and  FD2,  whereas  an
important drop off was achieved after freeze-drying by cycle FD3. However, in general
terms, lower ξ-potential values are obtained in formulations containing mannitol.
Table  3.  DLS  average  diameter  D,  PDI and  ξ-potential  of  PEC,  PEC-FD1,
PEC-FD1-M, PEC-FD2, PEC-FD2-M, PEC-FD3 and PEC-FD3-M, in 10 mM HEPES
buffer pH 7.5, at 25 ºC. Depicted results are the average from 3 different measurements
of the same sample.
Average size 
D 
(Mean ± SD) 
(nm)
PDI
(Mean ± SD)
ξ-potential
(Mean ± SD)
(mV)
PEC 267 ± 4 0.15 ± 0.02 18.7 ± 1.1
PEC-FD1 298 ± 1 0.28 ± 0.01 17.4 ± 3.7
PEC-FD1-M 574 ± 31 0.64 ± 0.05 16.9 ± 4.1
PEC-FD2 226 ± 4 0.25 ± 0.03 17.5 ± 1.5
PEC-FD2-M 226 ± 6 0.28 ± 0.01 17.2 ± 1.8
PEC-FD3 275 ± 16 0.37 ± 0.07 14.4 ± 2.1
PEC-FD3-M 464 ± 32 0.44 ± 0.05 11.3 ± 3.4
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Figure  1.  Particle  size  distribution  of  freshly  prepared  PEC,  and  PEC freeze-dried
following the protocol 2, with (PEC-FD2-M) and without (PEC-FD2) mannitol.
3.3 Cytotoxicity and hemocompatibility
It has been proposed that strong interaction of cationic nanoparticles with the cell
membrane  may  cause  damage  by  membrane  disruption,  leading  to  cell  death.41
Therefore investigation of the potential cytotoxicity of the PECs is important in order to
exclude biological responses due to cell death. Cell viability of PEC and PEC-RGD was
evaluated on HeLa (ovarian carcinoma) and on HMEC-1 (microvasculature endothelial
cells)  cell  lines.  HeLa is  a  reference cell  line,  routinely used in  cytotoxicity  assays.
HMEC-1 is an immortalized human microvascular endothelial cell line that retains the
morphologic, phenotypic and functional characteristics of normal human microvascular
endothelial cells.42 It was chosen because the vascular endothelium represents a target of
choice for therapeutic intervention in Fabry disease. Cells were exposed during 72 h to
different doses of PEC or PEC-RGD, up to 5.5 µg mL -1, and then evaluated using the
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MTT assay. For HeLa and HMEC-1 cells, cell viability slightly decreased up to values
around 80% for the highest concentration tested (Figure 2). 
To test the hemocompatibility of PEC and PEC-RGD, the percentage of hemolysis of
mouse RBC was assessed for different PEC or PEC-RGD concentrations up to 2.7 µg
mL-1. Hemolysis for both PEC and PEC-RGD was always lower than 1% for the tested
concentrations  (Figure  3).  These  results  indicate  that  both  PEC  and  PEC-RGD
cytotoxicity is very low and they do not induce hemolysis in concentrations below 5.5
µg mL-1.
Figure 2. Effect of PEC and PEC-RGD on HeLa (a) and HMEC-1 (b) cell viability. The
results presented correspond to the average of 3 independent experiments. 
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Figure 3.  Effect of PEC and PEC-RGD on the hemolysis of mice RBC. The results
presented correspond to the average of 3 independent experiments. 
3.4 Cell internalization 
We have demonstrated in a previous work that the GLA loaded PEC are easily taken
up by endothelial cells and localized in the lysosomal compartments, when incubated in
vitro for 2 h.5 In the present work, we aimed at comparing the uptake efficiency of PEC
and  PEC-RGD  by  endothelial  cells,  as  they  represent  the  target  of  choice  for
therapeutical  intervention.  HMEC-1  cells  were  incubated  with  fluorescently  labeled
PECs, PEC-Atto and PEC-Atto-RGD, for short periods of time, i.e. 10 and 20 min, and
PECs internalization was evaluated by flow cytometry. As shown in Figure 4a, 15.7 ±
0.5% and 26.3 ± 2.3% of the cells showed enhanced fluorescence when incubated with
PEC-Atto for 10 and 20 min, respectively, while incubation with PEC-Atto-RGD for 10
and  20  min  led  to  24.4  ±  1.8%  and  37.0  ±  1.8%  of  positive  cells,  respectively.
Interestingly,  the percentage of positive cells and mean fluorescence intensity (MFI),
both indicative of the amount of nanoparticles internalized by cells,  were higher  on
cultures incubated with the PEC-Atto-RGD as compared to those treated with PEC-Atto.
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Such  differences  were  increased  for  short  times  (10  min,  p  =  0.0129,  Figure  4),
indicating that, as expected, receptor mediated internalization through the RGD binding
of αvβ3 integrins is faster and more efficient than the non-targeted endocytic process.
Figure 4. Uptake of Atto 647N-labeled PEC and PEC-RGD (PEC-Atto and PEC-Atto-
RGD) in live HMEC-1. a) Flow cytometry quantitation of the fraction of cells that had
internalized PEC as the percentage of Atto 647N-positive cells among a given number
of cells counted and b) mean fluorescence intensity (MFI) of Atto 647N in the cells
normalized to the maximum fluorescence intensity. 
3.5 Activity in primary cultures: Gb3 loss in endothelial primary cultures of Fabry
mice
Since  GLA  activity  reduces  Gb3  deposits  within  the  lysosomes,  the  efficacy  of
different PECs to diminish the intracellular Gb3 deposits was assessed in cell cultures
and compared to  the activity  of  free GLA. The percentage of  Gb3 loss  of  primary
cultures of mouse aortic endothelial cells (MAEC) of GLA deficient mice was evaluated
after  simultaneous incubation with fluorescently labeled Gb3 (NBD-Gb3) and GLA,
PEC  or  PEC-RGD  in  different  concentrations.  Degradation  of  NBD-Gb3  by  GLA
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occurs exclusively inside the late endosomes/lysosomes, where the pH conditions are the
most favorable for the enzyme activity. 
In order to refer the intracellular activity to the specific activity of GLA in the
different samples, the enzymatic activity of free GLA, PEC and PEC-RGD was first
assessed  following  the  degradation  of  4-MUG  fluorometrically,  in  the  conditions
described in the Experimental section (section 2.10). The specific activity of the GLA is
in some extent altered by the encapsulation process, as detailed in Table 4. A decrease in
activity after encapsulation has previously been observed for GLA loaded TMC-based
PEC5 and  it  is  probably  related  to  the  more  difficult  accessibility  to  the  substrate.
Dissociation of the PECs and accessibility of the enzyme to the substrate is expected to
be easier in the lysosome, with presence of many degrading enzymes, than in the test
tube. 
Figure 5 displays the Gb3 loss, obtained from the reduction in fluorescence due
to the degradation of NBD-Gb3, plotted against the concentration of activity of GLA of
the free GLA, PEC or PEG-RGD suspensions. The GLA concentration is represented in
activity units (U mL-1) due to the variations in specific activity for the different samples
tested. The curves show higher efficacy for both PEC and PEC-RGD when compared to
free GLA, as there is a 50% loss of Gb3 (IC50) already at 7.6 ± 0.9 and 5.5 ± 1.5 mU
mL-1 activity for PEC and PEC-RGD, respectively, while for the free GLA this occurs at
an activity of 50.3 ± 8.1 mU mL-1. These results suggest that GLA is better internalized
by MAEC when loaded in the PECs, increasing significantly the efficacy (IC50 values
for the Gb3 loss is 7.6 ± 0.9 mU mL-1 for PEC while naked GLA requires 50.3 ± 8.1 mU
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mL-1). In addition, the slight decrease in IC50 for the RGD decorated PEC (IC50 values
of  5.5  ± 1.5  mU  mL-1)  may  be  associated  with  the  higher  internalization  degree
observed already in HMEC-1 when compared to the bare PECs.
Table 4. Specific enzymatic activity PEC, PEC-RGD and free GLA suspension tested in
vitro
Protein
concentration
(µg mL-1)
Activity (Mean ± SD)
 (µmol h-1 mg-1)  (U mL-1)
GLA 373 1533.5 ± 177.1 9.533 ± 1.101
PEC 16 487.9 ± 39.8 0.130 ± 0.011
PEC-RGD 17 406.3± 26.8 0.115 ± 0.008
Figure 5. Activity of PEC, PEG-RGD and free GLA in primary cultures (MAEC KO
cells). The mean percentage of Gb3 loss of three independent experiments is plotted vs.
GLA activity concentration. 
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The  enzymatic  activity  of  the  freeze-dried  PEC  was  tested  immediately  after
resuspension in MilliQ water, and compared with the specific activity of the stock PEC
suspension. Results in Table 5 show that the freeze-drying process not only does not
affect the enzymatic activity of the encapsulated GLA, but also helps to preserve its
activity, since all FD-PECs show higher enzymatic activity than the fresh PECs tested
after  4  days  of  preparation.  Besides,  the  presence  of  mannitol  in  the  freeze-drying
medium does not have a direct effect on the enzymatic activity in the test tube. Finally,
although all freeze-dried PECs display good enzymatic activity after resuspension, the
maximum activity is obtained after the freeze drying cycle 2 (FD2).
Table 5. Enzymatic  activity  GLA containing freeze-dried PECs and stock PEC and
GLA suspensions. All tests were performed within the first days after PECs synthesis
and immediately after resuspension, in the case of freeze-dried PECs.
Protein
concentration
(µg mL-1)
Activity (Mean ± SD)
(µmol h-1 mg-1) (U mL-1)
GLA 1452 1681 ± 165 40.69 ± 4.00
PEC 23 333.4 ± 6.7 0.106 ± 0.003
PEC-FD1 23 586.2 ± 12.5 0.191 ± 0.005
PEC-FD1-M 23 606.2 ±33.5 0.203 ± 0.013
PEC-FD2 23 808.3 ± 65.6 0.310 ± 0.025
PEC-FD2-M 23 783.0 ± 106 0.300 ± 0.041
PEC-FD3 23 549.6 ± 21.6 0.211 ± 0.008
PEC-FD3-M 23 582.9 ± 30.0 0.223± 0.012
26
Accordingly,  the  intracellular  activity  of  the  PEC-FD2  was  assessed  and
compared with that of the freshly prepared PECs. Figure 6 displays the Gb3 loss plotted
against  the  concentration  of  activity  of  GLA  for  PEC,  PEC-FD2 and  PEC-FD2-M
suspensions. Both PEC-FD2 and PEC-FD2-M display higher efficacy than PEC, with a
50% loss of Gb3 (IC50) at 1.5 ± 0.2 and 1.3 ± 0.2 mU mL-1 activity for PEC-FD2 and
PEC-FD2-M, respectively,  and at  5.9  ± 0.5  mU mL-1 for PEC, probably due to  the
stabilization of the PEC complex after freeze-drying procedure. 
Figure 6.  In vitro activity of GLA containing freeze-dried PECs in primary cultures
(MAEC KO cells): Gb3 loss vs. GLA activity after incubation with resuspended PEC-
FD2 and PEC-FD2-M, or freshly prepared PEC.
4. DISCUSSION
Pharmacological treatment of LSDs is in most cases based on the ERT with purified
recombinant enzymes. The lysosomal destiny of infused enzymes by ERT relies in the
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presence of M6P at the protein and its ability to interact with the cell membrane via
M6P  receptors.  Enzyme  loaded  in  nanoparticle-based  nanocarriers  is  a  promising
alternative to  increase the efficacy of ERT treatment  as they can provide a versatile
platform  to  tackle  several  issues  dealing  with  intracellular  delivery  of  therapeutic
macromolecules.  Encapsulation  within  nanocarries  can  influence  blood  circulation
times and protect biomacromolecules from protease degradation and immune system
reaction. Furthermore, they allow tailoring the interaction with the cell membrane and
release  of  the  cargo  by  tuning  the  nanoparticle  physicochemical  properties,
functionalization with specific ligands, etc, in order to tackle specific tissues, organs,
cell types, and even organelles. 
Here, we have developed a PEC based on the ionic interaction between the lysosomal
enzyme GLA, deficient in the LSD called Fabry disease, and TMC, using TPP as ionic
crosslinker.5 The ionic  nature  of  the  PECs has  the  advantage  of  simple  preparation
procedures,  due  to  the  self-assembling  nature  of  the  system,  which  is  of  great
importance  when  the  cargo  is  a  biomacromolecule,  sensitive  to  harsh  synthesis
conditions  like  high  temperatures,  solvents  or  extreme  pH.43 In  addition,  it  permits
tailoring of the nanoparticle properties by modifying only one of the PECs components,
the TMC in this case. Using this strategy, we have developed PECs capable to self-
assemble at neutral pH by simply mixing components and stirring, and disassemble at
endo-lysosomal acidic pH, where the GLA is most active. The PECs have average  D
between 170 and 250 nm and very low PDI (0.1-0.2) measured by DLS, and positive ξ-
potential in the range of 16-19 mV at pH 7.4 (Table 2), suggesting that the nanoparticles
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surface expose mainly TMC than GLA, as the protein is negatively charged at neutral
pH.44
It  has been proposed that the strong interaction of cationic nanoparticles  with the
negatively  charged  cell  membrane  may  cause  membrane  disruption,  leading  to  cell
death,41 but it is also evidence that the toxicity of cationic nanoparticles depends on cell-
specific uptake mechanisms and pathways.45 Following safety concerns for future in vivo
applications, we investigated the potential toxicity of the PECs on HeLa, a routinely
used cell  line for cytotoxicity evaluation,  and HMEC-1 cells, as vascular endothelial
cells  represent  the  main  target  for  therapeutics  in  Fabry  disease.19-21 For  PEC
concentrations up to 5.5 µg mL-1 cell viability is not significantly affected, maintained
around 80% (Figure 2). Besides, hemolysis of the PECs suspensions was always lower
than  1% when  tested  against  mouse  RBC  (Figure  3),  clearly  below  the  5%  value
considered as the toxicity threshold. These results are in agreement with other reports on
TMC  based  nanovectors  with  low  toxicity46 and  also  show  a  correlation  of  the
cytotoxicity  with other  structural  parameters  besides  surface charge,  like size of the
nanoparticles,  molecular  weight  of  chitosan  and  acetylation  degree.47 Moreover,  the
lowered  buffering  capacity  of  chitosan  after  methylation5 prevents  endo-lysosomal
disruption and scape,48 which in combination with the dissociation capacity of the PECs
at low pH5 and the eventual TMC degradation by lysosomal enzymes, may preserve
lysosomal function after PECs internalization.
In previous studies we demonstrated that the PECs were efficiently internalized by
HMEC-1  cells  in  vitro,  after  2  h  incubation,  with  endosomal/lysosomal  destination
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confirmed by multicolor fluorescence microscopy.5 This nonspecific cell uptake most
likely takes place by adsorptive endocytosis.49, 50 Here, we explored the introduction of
peptides ligands that include the RGD motif in the PECs structure, to target integrins
like  αvβ3, expressed  in  endothelial  cells  and  upregulated  during  inflammation  or
angiogenesis and also in Fabry patients.22-27,  51 Conjugation of c(RGDfk) to TMC is a
simple  procedure,  and allows obtaining  RGD-conjugated-PECs (PEC-RGD),  without
significant  alterations  of  the  particle  average  diameter  and  a  slight  decrease  in  ξ-
potential value (Table 2), probably due to the exposure of RGD peptide on the surface.
The PEC-RGD showed the same cell viability, when evaluated on HeLa and HMEC-1
cell lines (Figure 2), and hemocompatibility (Figure 3) of the PECs. Still, versatility of
the PECs may allow introducing other types of ligands to target for example ICAM-1.52,
53
Using a  similar  strategy,  by  conjugation  of  TMC with a  fluorescent  moiety  (Atto
647N), fluorescent PEC and PEC-RGD were prepared to follow cell uptake by FACS,
also maintaining average  D and with a minor decrease in  ξ-potential (Table 1). When
comparing the internalization of PEC and PEC-RGD by HMEC-1 after incubation for
short times, i.e. 10 and 20 min, an increase in the number of positive cells was observed
for  both  PEC and PEC-RGD over  time (Figure  4).  However,  statistically  significant
difference  in  the  amount  of  positive  cells  between PEC and PEC-RGD uptake  was
mainly observed at 10 min incubation time. It is important to take into account that, due
to the preparation method, it is not possible to control the location and orientation of the
RGD motif within the PEC. The addition of TMC and TMC-RGD solutions to the GLA
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+ TPP solution is done in subsequent steps, in order for the first complexes to be formed
with the TMC, and then complete the particle formation with the TMC-RGD. We expect
that the amount of RGD be higher on the outer layers of the PEC than on the core;
however,  we have no evidence to support this hypothesis. Still,  even when HMEC-1
internalization occurs fast and in great extent for both PEC and PEC-RGD, the enhanced
uptake  of  RGD  decorated  PEC  at  short  incubation  times  is  evidenced  (Figure  4),
suggesting a quick and efficient receptor-mediated uptake, or at least a combination of
both nonspecific and receptor-mediated endocytosis.
Preservation  of  enzymatic  activity  of  GLA  after  encapsulation  in  the  PECs  is
essential. A first, test following the degradation of 4-MUG fluorometrically revealed that
GLA in PECs is active, but shows a decrease in activity after encapsulation (Table 4).
This might be related to a hampered accessibility of the substrate because of a partial
association of the enzyme and TMC persisting at acidic pH. However, it is expected that
in  the  lysosomal  environment,  pH-triggered  release  will  be  accompanied  by  the
lysosomal enzymes degradation of TMC,54 facilitating enzyme-substrate interactions. In
order to have more representative results of PECs efficacy in vitro, the evaluation of the
degradation of NBD-Gb3 in primary GLA deficient cultures (Fabry mice) was assessed.
As shown, results were promising, as both PEC and PEC-RGD display higher activity in
MAEC KO cells than free GLA (Figure 5) with significantly lower IC50 (50.3 mU mL-1
for GLA and 7.6 and 5.5 mU mL-1 for PEC and PEC-RGD, respectively). This means
that  an  important  increase  in  intracellular  activity  is  happening  when  GLA  is
encapsulated  in  PECs  respect  to  the  free  GLA,  even  when  certain  loss  of  specific
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activity of GLA after encapsulation is happening. Consequently, less activity units of
GLA are  necessary  to  degrade  Gb3 when  the  enzyme is  encapsulated.  It  has  been
recently reported the increase of GLA activity when associated to liposomes,11 which
has been related to the immobilization of the enzyme onto the lipid bilayer. A similar
effect may be happening when GLA is interacting with TMC after PECs are dissociated
inside the endo/lysosomal compartments, and partial association with TMC may still
take  place.  Moreover,  an  increased  efficiency  due  to  the  RGD  ligand  is  detected,
probably due to a  higher  internalization degree,  or even to a more favorable uptake
mechanism. It is well documented that nonspecific cell uptake of nanocarriers occurs
mainly by endocytic process,55 and integrin-mediated internalization occurs when the
carrier interacts with the cell surface receptors and are taken up into the target cells via
receptor-mediated endocytosis. In both cases, the resulting endocytic vesicles fuse to
form early endosomes and then mature into late endosomes which ultimately become
part of the lysosomes.22 The occurrence of the uptake via the two different mechanisms
is here suggested by the faster internalization observed in vitro for PEC-RGD than for
PEC. This opens the possibility of an alternative glycosylation independent targeting53, 56
for  ERT,  and  might  facilitate  the  use  of  non-glycosylated  or  partially  glycosylated
enzymes for treatment of LSD via ERT. Thus, GLA encapsulation will also endure a
protection  effect  against  GLA  opsonization  in  the  blood  stream  as  previously
demonstrated for other systems.57,  58 Increased cellular levels of GLA or its activity in
plasma have recently been reported on systems where GLA is also stabilized by other
means, such as crosslinking and PEGylation, giving a prolonged circulatory half-life,57
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or by the use of chaperones like Migalastat HCl.58 Moreover, the increased advantage in
the  intracellular  efficacy  of  the  GLA  when  associated  to  the  TMC  in  the  PECs,
particularly when decorated with RGD targeting moieties, would likely be evidenced
when testing them in in vivo Fabry murine experimental models.
Finally,  we  have  demonstrated  that  the  PECs  can  be  freeze-dried  (FD)  under
controlled conditions to be preserved and administrated thereafter. We explored several
FD  cycles  and  the  introduction  of  mannitol  (PEC-FD-M),  commonly  used  as  a
cryoprotector but also to achieve isosmotic solutions, to see its effect on the structure
and properties of PEC-FD. Evaluating the physicochemical properties of the PECs after
resuspension and the GLA enzymatic activity after the whole cycle allowed determining
the optimal FD conditions (FD2), i.e. fasting freezing at -40 º C.  Using this cycle, the
size and  ξ-potential of the PECs after resuspension was not altered (Table 3) and the
specific enzymatic activity of the GLA was preserved (Table 5), for both PECs with and
without  mannitol.  The  presence  of  mannitol  did  not  introduce  any  change  in
physicochemical of the PECs or the biochemical properties of the loaded GLA. PEC-
FD2 (as  well  as  PEC-FD2-M) showed higher  specific enzymatic  activity  than  fresh
PECs, probably due to the fact that the tests were performed 4 days after preparation,
and  while  fresh  PECs  could  lose  part  of  the  GLA  structure  and  activity,  FD-PEC
preserved it.59 Not only was a higher specific enzymatic activity observed for PEC-FD
but also a significant increase in NBD-Gb3 loss when tested on MAEC KO cells  in
vitro, with IC50 values of 5.9 mU mL-1 for PEC and 1.5 and 1.3 mU mL-1 for PEC-FD2
and  PEC-FD2-M,  respectively  (Figure  6).  Subsequently,  when  comparing  PEC-FD2
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with the free GLA in suspension, the increase in efficacy is very high, with IC50 values
from 50.3 to 1.5 mU mL-1. The FD process is a crucial step to preserve the PECs stable
and active, and it could also serve as a way to slightly concentrate the sample when
needed.
5. CONCLUSIONS
We have developed a versatile protein lysosomal delivery PEC based on the negatively
charged  lysosomal  enzyme  GLA,  deficient  in  the  LSD  Fabry  disease,  and  TMC,
ionically  crosslinked  with  TPP.  Given  its  simple  preparation  strategy,  it  allows
functionalization via conjugation of TMC with different moieties, like fluorophores and
ligands, and also changing the cargo protein to tackle other LSDs. We evaluated the
intracellular activity of the GLA loaded PECs, and the possibility of enhancing their
efficacy as lysosomal delivery vectors in endothelial cells by introducing the RGD motif
in the nanocarriers (PEC-RGD). We successfully  prepared PEC and PEC-RGD with
good physicochemical properties, low cytotoxicity and good hemocompatibility. PECs
were  efficiently  taken  up  by  endothelial  cells  in  vitro,  and  the  internalization  was
significantly higher for PEC-RGD than for PECs at short incubation times. Even more,
we demonstrated an enhanced efficacy of PEC and PEC-RGD as compared to free GLA
when evaluating the intracellular activity in primary cultures of GLA deficient mice.
Relevantly, we optimized a FD protocol that allowed maintaining the physicochemical
properties of the PECs while improving the biochemical ones, preserving the specific
enzymatic activity of GLA and enhancing the efficacy in vitro in MAEC KO cells. The
FD process is essential to preserve the PECs stable and active, and also could serve as a
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way to concentrate the sample when needed. Overall,  the greater  in vitro efficacy of
PECs on primary cultures together with the enhanced specificity via the introduction of
RGD ligands to enable more of the GLA reaching the endothelial cells, indicate the
potential of PECs to enhance its efficacy in ERT in vivo and to reduce the amount of
GLA and the frequency of administration required in current ERT of Fabry patients.
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